593 related articles for article (PubMed ID: 17199714)
1. Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults.
Yuen KC; Dunger DB
Diabetes Obes Metab; 2007 Jan; 9(1):11-22. PubMed ID: 17199714
[TBL] [Abstract][Full Text] [Related]
2. Impact of treatment with recombinant human GH and IGF-I on visceral adipose tissue and glucose homeostasis in adults.
Yuen KC; Dunger DB
Growth Horm IGF Res; 2006 Jul; 16 Suppl A():S55-61. PubMed ID: 16624605
[TBL] [Abstract][Full Text] [Related]
3. Visceral obesity, impaired glucose tolerance, metabolic syndrome, and growth hormone therapy.
Attallah H; Friedlander AL; Hoffman AR
Growth Horm IGF Res; 2006 Jul; 16 Suppl A():S62-7. PubMed ID: 16624603
[TBL] [Abstract][Full Text] [Related]
4. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency.
Yuen KC; Frystyk J; White DK; Twickler TB; Koppeschaar HP; Harris PE; Fryklund L; Murgatroyd PR; Dunger DB
Clin Endocrinol (Oxf); 2005 Oct; 63(4):428-36. PubMed ID: 16181235
[TBL] [Abstract][Full Text] [Related]
5. Persisting effects on fasting glucose levels and insulin sensitivity after 6 months of discontinuation of a very low-dose GH therapy in adults with severe GH deficiency.
Yuen KC; Dunger DB
Clin Endocrinol (Oxf); 2006 May; 64(5):549-55. PubMed ID: 16649975
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans.
Hussain MA; Schmitz O; Mengel A; Glatz Y; Christiansen JS; Zapf J; Froesch ER
J Clin Invest; 1994 Sep; 94(3):1126-33. PubMed ID: 8083353
[TBL] [Abstract][Full Text] [Related]
7. Insulin sensitivity in growth hormone (GH)-deficient adults and effect of GH replacement therapy.
Alford FP; Hew FL; Christopher MC; Rantzau C
J Endocrinol Invest; 1999; 22(5 Suppl):28-32. PubMed ID: 10442567
[TBL] [Abstract][Full Text] [Related]
8. Evidence for distinct effects of GH and IGF-I in the metabolic syndrome.
Maison P; Balkau B; Souberbielle JC; Cunin P; Vol S; Macquin-Mavier I; Eschwège E;
Diabet Med; 2007 Sep; 24(9):1012-8. PubMed ID: 17535291
[TBL] [Abstract][Full Text] [Related]
9. Changes in insulin sensitivity induced by short-term growth hormone (GH) and insulin-like growth factor I (IGF-I) treatment in GH-deficient adults are not associated with changes in adiponectin levels.
Schmid C; Bianda T; Zwimpfer C; Zapf J; Wiesli P
Growth Horm IGF Res; 2005 Aug; 15(4):300-3. PubMed ID: 16054413
[TBL] [Abstract][Full Text] [Related]
10. The effects of GH replacement in adult GH-deficient patients: changes in body composition without concomitant changes in the adipokines and insulin resistance.
Hana V; Silha JV; Justova V; Lacinova Z; Stepan JJ; Murphy LJ
Clin Endocrinol (Oxf); 2004 Apr; 60(4):442-50. PubMed ID: 15049958
[TBL] [Abstract][Full Text] [Related]
11. The reduction in visceral fat mass in response to growth hormone is more marked in men than in oestrogen-deficient women.
Franco C; Koranyi J; Brandberg J; Lönn L; Bengtsson BK; Svensson J; Johannsson G
Growth Horm IGF Res; 2009 Apr; 19(2):112-20. PubMed ID: 18752977
[TBL] [Abstract][Full Text] [Related]
12. Impact of 5 years of growth hormone replacement therapy on cardiovascular risk factors in growth hormone-deficient adults.
Cenci MC; Conceição FL; Soares DV; Spina LD; Brasil RR; Lobo PM; Michmacher E; Vaisman M
Metabolism; 2008 Jan; 57(1):121-9. PubMed ID: 18078869
[TBL] [Abstract][Full Text] [Related]
13. Commencing growth hormone replacement in adults with a fixed low dose. Effects on serum lipoproteins, glucose metabolism, body composition, and cardiovascular function.
Gillberg P; Bramnert M; Thorén M; Werner S; Johannsson G
Growth Horm IGF Res; 2001 Oct; 11(5):273-81. PubMed ID: 11735245
[TBL] [Abstract][Full Text] [Related]
14. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
15. Metabolic implications of growth hormone therapy.
Perrini S; Carreira MC; Conserva A; Laviola L; Giorgino F
J Endocrinol Invest; 2008 Sep; 31(9 Suppl):79-84. PubMed ID: 19020393
[TBL] [Abstract][Full Text] [Related]
16. A transgenic model to determine the physiological role of liver-derived insulin-like growth factor I.
Sjögren K; Jansson JO; Isaksson OG; Ohlsson C
Minerva Endocrinol; 2002 Dec; 27(4):299-311. PubMed ID: 12511852
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance.
Ranke MB
Trends Endocrinol Metab; 2005; 16(4):190-7. PubMed ID: 15860416
[TBL] [Abstract][Full Text] [Related]
18. GH sensitivity of GH-deficient adults is dependent on gender but not timing of onset.
Columb B; Smethurst LE; Mukherjee A; Jostel A; Shalet SM; Murray RD
Clin Endocrinol (Oxf); 2009 Feb; 70(2):281-6. PubMed ID: 18702681
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
[TBL] [Abstract][Full Text] [Related]
20. Role of growth hormone in chronic heart failure: therapeutic implications.
Volterrani M; Giustina A; Manelli F; Cicoira MA; Lorusso R; Giordano A
Ital Heart J; 2000 Nov; 1(11):732-8. PubMed ID: 11110515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
